S.horowits_Logo

Ran Vogel

Partner

  • Print
הורדת vCard vCard
About
Core Capabilities
Notable Representations
recognition
Education
Admission

Ran Vogel serves as a leading expert in Patents and Intellectual Property law, representing Fortune 500 companies, multinational corporations, technology companies, universities, and start-ups.

His practice focuses on complex intellectual property matters across pharmaceutical, life sciences, telecommunications, defence sector, and technology industries. Ranked by IAM Patent, Chambers and Legal 500 as one of Israel’s leading Intellectual Property litigators, he provides comprehensive litigation services before all levels of Israeli civil courts and arbitration tribunals. His expertise encompasses enforcement strategy, infringement and validity issues, and strategic brand management. Ran advises companies of all types on building intellectual property strategy and advises extensively in the field of artificial intelligence.

"Great communication skills, creative arguments, leading negotiations and excellent witness interrogation preparation"

Chambers & Partners

Ran actively participates in legislative processes for Israel’s Patent Law amendments and regulations affecting the pharmaceutical and life science sector. Ran holds key positions at AIPPI, both internationally and locally cementing his role in shaping international intellectual property policy.

Core Capabilities

  • Patent Litigation and Enforcement: Comprehensive representation in complex patent infringement cases, validity challenges, and enforcement actions
  • Trade Secrets Protection and Litigation: Strategic counsel on trade secret identification, protection protocols, misappropriation claims, and enforcement litigation
  • Trademark and Copyright Protection: Full-spectrum IP protection including registration, prosecution, opposition proceedings, and infringement litigation
  • Intellectual Property Aspects of Artificial Intelligence: Specialized expertise in AI-related IP matters including patentability of AI innovations, data protection, algorithmic trade secrets, and regulatory compliance
  • Life Science and Pharmaceutical Regulatory Matters: Complex regulatory and IP guidance including drug approval processes, patent linkage, regulatory exclusivity, and billion-dollar patent portfolio management
  • Anti-counterfeiting and Brand Enforcement: Comprehensive brand protection strategies including anti-counterfeiting investigations, customs enforcement, and coordinated international enforcement actions
  • Parallel Imports Advisory: Strategic counsel on parallel importation issues, exhaustion of rights, trademark and patent implications of gray market goods across multiple jurisdictions
  • Patent-term Extensions: Expert guidance on patent term extension applications, regulatory processes, and strategic patent portfolio management for pharmaceutical and medical device clients

Notable Representations

  • Represents Teva Pharmaceuticals in numerous multinational billion-dollar patent litigations
  • Representing Bright Data (scaping data company), in numerous patent litigation
  • Representing Versah in multinational patent litigation
  • Representing Aleph Farm (cultivated meat company), in patent litigation
  • Defends Strauss Group in IP rights and franchise violations
  • Represents Israel’s three largest cellphone companies in patent infringement
  • Leads patent opposition proceedings for Thales in advanced technology

recognition

Education

  • LL.B., magna cum laude, Tel Aviv University, 1996

Admission

  • Israel Bar

Contact

+972.3.5670700

ranv@s-horowitz.com

Expertise

Intellectual Property

Languages

Hebrew, English

Ran Vogel

Contact

+972.3.5670700

ranv@s-horowitz.com

Expertise

Intellectual Property
AI Commercial and Regulation
AI IP
Copyrights and Related Rights
View more >

Languages

Hebrew, English

News & Insights:

By Ran Vogel

Access our legal insights, thought leadership and expert analysis

Updates

From Patents That Save Lives to Patents That Save the Planet: AIPPI’s Landmark Resolution on Compulsory Licensing

AIPPI’s Resolution extends emergency patent measures to climate tech while preserving innovation incentives through fair compensation, strict limits, and robust safeguards for patentees.
Read

Updates

Authorship’s Future: AIPPI’s 2025 Resolution and AI-Era Copyright

As courts and creators grapple with defining human vs. AI authorship, AIPPI’s 2025 Resolution offers a clear framework on AI & Copyright—addressing data use, liability, transparency, and AI-generated works to guide the next era of copyright law.
Read

Updates

Code of Practice for General-Purpose AI Models Adopted: What You Need to Know Now

On 10 July 2025, the European Commission received the final version of the Code of Practice for General-Purpose AI Models (GPAI).
Read

Updates

Intellectual Property in Insolvency Proceedings

In insolvency, knowing the true value of a startup’s intellectual property is crucial—it often defines whether the business can be revived, sold, or lost entirely.
Read

Updates

Copyrighted Works and Training AI Models: The U.S. Copyright Office’s Position

The U.S. Copyright Office published a groundbreaking, non-binding, pre-publication report examining whether using copyrighted works to train generative AI models falls within “fair use.
Read

Updates

U.S. Court: Copyright Protection Requires a Human Author

Thaler v. Perlmutter: The court affirmed that under the Copyright Act, only a human can be recognized as the “author” of a work
Read

Updates

AIPPI Answer the Core Questions of Parody defence in Copyright

The International Association for the Protection of Intellectual Property (AIPPI) has taken a significant step toward harmonizing the defense of parody in copyright law.
Read

Updates

AIPPI Tackles Unfounded IP Infringement Allegations

The Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI), or the International Association for the Protection of Intellectual Property
Read

Articles

Navigating AI Regulation in Israel: Legal Insights

As the landscape of Artificial Intelligence (AI) rapidly evolves, it raises essential legal questions.
Read

Articles

Novartis’ PI Motion re Gilenya® Denied: Generic Entry Does Not Necessarily Cause “Catastrophic Damages” to the Brand

The Israeli Tax Authority has issued groundbreaking guidance on SAFE instruments, providing much-needed clarity for venture capital investments.
Read
For all News & Insights

Position Application

Subscribe

Get the latest updates straight to your inbox

SHARE

Facebook
LinkedIn
WhatsApp
Email
Print